Related Experiment Video
Updated: Aug 10, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Temozolomide for recurrent high-grade glioma
1Department of Oncology, University of Western Ontario, London Regional Cancer Centre, London, Ontario, Canada.
Seminars in Oncology
|September 11, 2001
Summary
Temozolomide offers a new oral treatment for high-grade gliomas, improving survival and quality of life. This chemotherapy agent shows efficacy in recurrent malignant glioma, providing a valuable therapeutic option.
Area of Science:
- Neuro-oncology
- Medical oncology
- Clinical pharmacology
Background:
- High-grade malignant gliomas, including anaplastic astrocytoma and glioblastoma multiforme, have a poor prognosis despite aggressive treatments.
- Tumor recurrence is common, and existing therapies offer limited enduring responses and negatively impact patient quality of life.
- Novel therapeutic strategies are essential to enhance symptom control, improve quality of life, and extend progression-free and overall survival.
Purpose of the Study:
- To evaluate the efficacy and safety of temozolomide, a novel oral antineoplastic agent, in patients with high-grade gliomas.
- To compare temozolomide with procarbazine in patients with glioblastoma multiforme regarding survival and quality of life.
- To assess the response rate and quality of life in patients with relapsed anaplastic astrocytoma treated with temozolomide.
Main Methods:
- A pivotal randomized international phase II trial compared temozolomide (n=112) with procarbazine (n=113) in glioblastoma multiforme patients.
- A large multicenter single-arm trial (N=162) evaluated temozolomide in patients with relapsed anaplastic astrocytoma.
- Quality of life was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire and brain-cancer-specific symptoms.
Main Results:
- Temozolomide significantly improved median and 6-month progression-free survival and 6-month overall survival compared to procarbazine in glioblastoma multiforme.
- Patients receiving temozolomide demonstrated superior responses in all seven tested quality-of-life domains.
- Temozolomide showed an impressive response rate in relapsed anaplastic astrocytoma, with patients maintaining or improving quality of life.
Conclusions:
- Temozolomide is an effective oral chemotherapy agent for high-grade gliomas, offering improved survival outcomes.
- The drug provides significant benefits in quality of life for patients with glioblastoma multiforme and anaplastic astrocytoma.
- Temozolomide presents a valuable therapeutic option for recurrent malignant glioma, characterized by a predictable safety profile, clinical efficacy, and convenient administration.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...